FYERS
Home
/
Stocks
/
Results
/
Shukra Pharmaceuticals Results

Shukra Pharmaceuticals Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
28%38%-1%74%
68%159%71%130%
-104%49%75%
13%23%30%30%

Peer Comparison

Symbol
SUNPHARMA-A
DIVISLAB-A
TORNTPHARM-A
ZYDUSLIFE-A
CIPLA-A
LAURUSLABS-A
MANKIND-A
DRREDDY-A
AUROPHARMA-A
LUPIN-A
SHUKRAPHAR-B
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,870.65₹447476 Cr3712.0762.82₹11479 Cr
9,632.75₹254764 Cr87.134.04128.41₹2568 Cr
4,963.25₹189423 Cr86.8516.7297.06₹2163 Cr
1,169.1₹116658 Cr25.859.4262.53₹5040 Cr
1,388.2₹111484 Cr33.089.7757.87₹3879 Cr
2,045.8₹109943 Cr100.556.829.25₹889 Cr
2,489.95₹101712 Cr49.7913.7571.08₹1913 Cr
1,204.9₹101005 Cr31.355.3263.99₹4196 Cr
1,729.55₹99253 Cr26.7317.9596.84₹3505 Cr
2,107.5₹96031 Cr17.3730.95154.35₹5333 Cr
55.6₹2509 Cr69.610.340.9₹22 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Jun 2025Mar 2025Dec 2024
₹24 Cr₹6 Cr₹39 Cr₹5 Cr₹13 Cr₹11 Cr
₹54 L₹95 L₹82 L₹1 Cr₹1 Cr₹1 Cr
₹24 Cr₹7 Cr₹40 Cr₹7 Cr₹15 Cr₹12 Cr
₹5 Cr₹7 Cr₹13 Cr₹5 Cr₹7 Cr₹7 Cr
₹20 Cr₹2 Cr₹28 Cr₹2 Cr₹9 Cr₹5 Cr
₹43 L₹26 L₹28 L₹27 L₹27 L₹15 L
₹18 Cr₹38 L₹27 Cr₹1 Cr₹8 Cr₹4 Cr
₹13 Cr-₹2 Cr₹20 Cr₹1 Cr₹5 Cr₹3 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010Mar 2009
——————————————————
₹44 Cr₹44 Cr₹11 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹10 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr
₹5 Cr₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹41 Cr₹19 Cr₹47 Cr₹21 Cr₹15 Cr₹14 Cr₹14 Cr₹14 Cr₹13 Cr₹13 Cr₹13 Cr₹12 Cr₹12 Cr-₹11 Cr-₹8 Cr-₹8 Cr-₹9 Cr-₹9 Cr
₹41 Cr₹19 Cr₹47 Cr₹21 Cr₹15 Cr₹14 Cr₹14 Cr₹14 Cr₹13 Cr₹13 Cr₹13 Cr₹12 Cr₹12 Cr-₹11 Cr-₹8 Cr-₹8 Cr-₹9 Cr-₹9 Cr
₹90 Cr₹63 Cr₹58 Cr₹25 Cr₹16 Cr₹16 Cr₹15 Cr₹15 Cr₹15 Cr₹15 Cr₹14 Cr₹14 Cr₹14 Cr-₹43 L₹1 Cr₹52 L-₹16 L-₹45 L
₹3 Cr₹2 Cr₹1 Cr₹90 L₹85 L₹66 L₹0₹0₹0₹0₹0₹0₹0₹0₹0₹69 L₹6 Cr₹6 Cr
₹69 L₹1 Cr₹1 Cr₹3 Cr₹2 Cr₹9 Cr₹8 Cr₹6 Cr₹4 Cr₹4 L₹4 L₹1 Cr₹31 L₹10 Cr₹10 Cr₹30 L₹30 L₹33 L
₹1 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹99 L₹99 L₹99 L
₹11 L₹13 L₹11 L₹11 L₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹4 Cr₹7 Cr₹6 Cr₹7 Cr₹6 Cr₹13 Cr₹11 Cr₹9 Cr₹6 Cr₹3 Cr₹2 Cr₹3 Cr₹2 Cr₹12 Cr₹13 Cr₹2 Cr₹7 Cr₹7 Cr
——————————————————
₹10 Cr₹9 Cr₹7 Cr₹34 Cr₹9 Cr₹5 Cr₹6 Cr₹3 Cr₹2 Cr₹1 Cr₹52 L₹71 L₹2 Cr₹1 Cr₹1 Cr₹4 Cr₹2 Cr₹2 Cr
₹5 Cr₹5 Cr₹6 Cr₹9 Cr₹3 Cr₹93 L₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹7 L₹73 L
₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹4 Cr₹0₹0
₹8 Cr₹3 Cr₹90 L₹10 L₹32 L₹77 L₹52 L₹85 L₹73 L₹58 L₹21 L₹17 L₹17 L₹29 L₹70 L₹52 L₹67 L₹73 L
₹23 Cr₹17 Cr₹14 Cr₹43 Cr₹12 Cr₹7 Cr₹7 Cr₹4 Cr₹3 Cr₹2 Cr₹73 L₹88 L₹2 Cr₹2 Cr₹2 Cr₹9 Cr₹3 Cr₹4 Cr
₹117 Cr₹87 Cr₹78 Cr₹75 Cr₹35 Cr₹36 Cr₹34 Cr₹28 Cr₹24 Cr₹19 Cr₹17 Cr₹18 Cr₹18 Cr₹14 Cr₹16 Cr₹11 Cr₹9 Cr₹11 Cr
₹6 Cr₹1 Cr₹1 Cr₹0₹1 Cr₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹5 Cr₹4 Cr₹3 Cr₹5 Cr₹3 Cr₹10 Cr₹8 Cr₹6 Cr₹4 Cr₹4 L₹4 L₹1 Cr₹31 L₹10 Cr₹10 Cr₹5 Cr₹6 Cr₹6 Cr
——————————————————
₹49 Cr₹43 Cr₹41 Cr₹40 Cr₹35 Cr₹34 Cr₹32 Cr₹29 Cr₹26 Cr₹21 Cr₹20 Cr₹20 Cr₹19 Cr₹19 Cr₹11 Cr₹10 Cr₹10 Cr₹10 Cr
₹27 Cr₹24 Cr₹21 Cr₹19 Cr₹18 Cr₹16 Cr₹14 Cr₹13 Cr₹12 Cr₹11 Cr₹11 Cr₹10 Cr₹10 Cr₹9 Cr₹8 Cr₹8 Cr₹7 Cr₹7 Cr
₹22 Cr₹19 Cr₹20 Cr₹20 Cr₹18 Cr₹18 Cr₹17 Cr₹16 Cr₹14 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹2 Cr₹2 Cr₹3 Cr₹3 Cr
₹12 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹0₹5 L₹5 L₹5 L₹5 L
₹3 L₹0₹0₹0₹0₹19 L₹5 L₹5 L₹5 L₹4 L₹4 L₹3 L₹5 L₹1 L₹1 L₹0₹0₹0
₹3 L₹0₹0₹0₹0₹19 L₹5 L₹5 L₹5 L₹4 L₹4 L₹3 L₹5 L₹1 L₹1 L₹0₹0₹0
₹34 Cr₹21 Cr₹22 Cr₹22 Cr₹19 Cr₹20 Cr₹19 Cr₹17 Cr₹16 Cr₹12 Cr₹11 Cr₹11 Cr₹11 Cr₹10 Cr₹2 Cr₹2 Cr₹3 Cr₹3 Cr
——————————————————
₹14 Cr₹10 Cr₹2 Cr₹3 Cr₹4 Cr₹2 Cr₹1 Cr₹27 L₹14 L₹32 L₹44 L₹1 Cr₹1 Cr₹1 Cr₹92 L₹64 L₹23 L₹14 L
₹23 Cr₹9 Cr₹25 Cr₹30 Cr₹7 Cr₹10 Cr₹8 Cr₹5 Cr₹3 Cr₹2 Cr₹94 L₹52 L₹55 L₹1 Cr₹4 Cr₹5 Cr₹4 Cr₹5 Cr
₹6 Cr₹12 Cr₹10 Cr₹4 Cr₹29 L₹50 L₹13 L₹25 L₹6 L₹52 L₹2 Cr₹59 L₹51 L₹8 L₹4 L₹24 L₹17 L₹15 L
₹30 Cr₹19 Cr₹6 Cr₹8 Cr₹17 L₹14 L₹1 Cr₹2 Cr₹2 Cr₹42 L₹45 L₹99,292₹37,265₹0₹0₹0₹10 L₹0
₹11 Cr₹16 Cr₹13 Cr₹8 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹2 Cr₹4 Cr₹5 Cr₹80 L₹8 Cr₹3 Cr₹2 Cr₹2 Cr
₹84 Cr₹65 Cr₹56 Cr₹53 Cr₹16 Cr₹16 Cr₹14 Cr₹11 Cr₹8 Cr₹7 Cr₹6 Cr₹7 Cr₹7 Cr₹3 Cr₹14 Cr₹9 Cr₹7 Cr₹8 Cr
₹61 Cr₹48 Cr₹42 Cr₹11 Cr₹3 Cr₹9 Cr₹7 Cr₹7 Cr₹6 Cr₹5 Cr₹5 Cr₹6 Cr₹5 Cr₹2 Cr₹12 Cr₹18 L₹4 Cr₹4 Cr
₹117 Cr₹87 Cr₹78 Cr₹75 Cr₹35 Cr₹36 Cr₹34 Cr₹28 Cr₹24 Cr₹19 Cr₹17 Cr₹18 Cr₹18 Cr₹14 Cr₹16 Cr₹11 Cr₹9 Cr₹11 Cr
₹2₹1₹53₹65₹104₹100₹98₹98₹96₹93₹90₹89₹88-₹0₹2₹1-₹0-₹0
₹2₹1₹1₹16₹22₹100₹98₹98₹96₹93₹90₹89₹88-₹0₹2₹1-₹0-₹0

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
₹29 Cr₹13 Cr₹20 Cr₹4 Cr₹1 Cr₹10 L₹17 L₹72 L₹95 L₹1 Cr₹35 L₹3 Cr-₹70 L-₹3 Cr₹95 L₹68 L₹29 L
₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹2 Cr₹96 L₹77 L₹47 L₹45 L₹5 L₹60 L₹3 Cr-₹2 Cr₹42 L₹67 L
-₹27 Cr-₹4 Cr-₹26 Cr-₹3 Cr₹5 Cr-₹1 Cr-₹51 L-₹1 Cr-₹74 L-₹1 Cr₹2 Cr-₹4 Cr-₹3 Cr₹10 Cr-₹7 Cr₹54 L-₹48 L
₹5 Cr₹12 Cr-₹5 Cr₹3 Cr₹8 Cr₹54 L₹1 Cr₹41 L₹98 L₹10 L₹3 Cr-₹2 Cr-₹3 Cr₹11 Cr-₹8 Cr₹2 Cr₹48 L
₹3 Cr₹8 Cr-₹5 Cr₹3 Cr₹8 Cr₹54 L₹1 Cr₹26 L₹84 L-₹29 L₹3 Cr-₹2 Cr-₹3 Cr₹10 Cr-₹7 Cr₹2 Cr₹5 L
-₹14 Cr-₹1 Cr-₹1 Cr-₹4 Cr-₹2 Cr-₹2 Cr-₹3 Cr-₹2 Cr-₹5 Cr-₹93 L-₹41 L₹73 L₹2 Cr-₹11 Cr₹2 Cr₹6 L₹12 L
₹5 Cr-₹5 Cr₹12 Cr₹5 Cr-₹7 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹0-₹1 Cr₹1 Cr₹2 Cr₹78 L₹5 Cr-₹2 Cr-₹15 L
-₹6 Cr₹2 Cr₹6 Cr₹4 Cr-₹21 L₹38 L-₹12 L₹18 L-₹46 L-₹1 Cr₹1 Cr₹8 L₹43 L₹4 L-₹20 L₹7 L₹2 L
₹12 Cr₹10 Cr₹4 Cr₹29 L₹50 L₹13 L₹25 L₹6 L₹52 L₹2 Cr₹59 L₹51 L₹8 L₹4 L₹24 L₹17 L₹15 L
₹6 Cr₹12 Cr₹10 Cr₹4 Cr₹29 L₹50 L₹13 L₹25 L₹6 L₹52 L₹2 Cr₹59 L₹51 L₹8 L₹4 L₹24 L₹17 L

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)56.35
Volume (₹)1.38 L
High (₹)57.34
Upper Circuit68.31
Low (₹)55.11
Lower Circuit45.55
Prev Close56.93
52W High (₹)65.26
Price55.60
52W Low (₹)26.30

Share Market Cap & Key Ratios Overview

M.Cap (₹)2509.40 Cr
Div. Yield (%)0.02
PE Ratio69.61
Debt to Equity0.06
Price to Book15.73
Book Value1.93
EPS (TTM)0.82
Face Value1.00
ROE (%)29.94

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMA-ANSE
DIVISLAB-ANSE
TORNTPHARM-ANSE
ZYDUSLIFE-ANSE
CIPLA-ANSE
LAURUSLABS-ANSE
MANKIND-ANSE
DRREDDY-ANSE
AUROPHARMA-ANSE
LUPIN-ANSE
SHUKRAPHAR-BNSE
LTP
1W Low
1W High
Market cap (₹)
1870.65+35.15 (1.92%)
1835.50
1890.40
4,47,476Cr
9632.75+265.75 (2.84%)
9305.95
9739.85
2,54,764Cr
4963.25+159 (3.31%)
4864.80
5010
1,89,423Cr
1169.1+16.1 (1.40%)
1152
1178.05
1,16,658Cr
1388.2+16.75 (1.22%)
1364
1404.35
1,11,484Cr
2045.8+90.55 (4.63%)
1964.50
2054.55
1,09,943Cr
2489.95+171.95 (7.42%)
2302.30
2492.65
1,01,712Cr
1204.9+33.8 (2.89%)
1186.20
1221.60
1,01,005Cr
1729.55-5.45 (-0.31%)
1690
1739.60
99,253Cr
2107.5-37.2 (-1.73%)
2084.50
2129.85
96,031Cr
55.6-0.36 (-0.64%)
54.97
59.76
2,509Cr

Shukra Pharmaceuticals Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹19.68Cr; with other income of ₹54Lakh, profit before interest and tax came to ₹18.6Cr. Interest expense was ₹43Lakh; PBT before exceptional items stood at ₹18.17Cr. Cost mix (full year): raw materials ₹11.75Cr; employee cost ₹5.47Cr; depreciation ₹1.08Cr; other expenses ₹4.38Cr. Basis: consolidated annual results.

Shukra Pharmaceuticals Ltd Quaterly Results Key Takeaways

Shukra Pharmaceuticals Ltd reported ₹23.52Cr total income from operations in Jun 2026, softer than ₹6.32Cr in Mar 2026 but higher than ₹13.27Cr in Mar 2025. Operating profit (before other income, interest and exceptional items) was ₹19.68Cr; with other income of ₹54Lakh, profit before interest and tax came to ₹18.6Cr. Interest expense was ₹43Lakh, taking profit before tax to ₹18.17Cr. After tax of ₹5.21Cr, profit after tax stood at ₹12.96Cr (vs ₹-₹1.72Cr in Mar 2026 and ₹5.39Cr in Mar 2025).